Successful management of refractory immune-mediated enterocolitis with cyclosporine

Eur J Cancer. 2020 May:131:37-39. doi: 10.1016/j.ejca.2020.02.014. Epub 2020 Apr 8.

Authors

David Pesántez¹, Elia Seguí¹, Ingrid Ordás², Marga Viladot¹, Ana Arance³

Affiliations

¹ Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
² IBD Unit, Gastroenterology Department, Hospital Clínic of Barcelona, CIBERehd, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
³ Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: AMARANCE@clinic.cat.

PMID: 32278241
DOI: 10.1016/j.ejca.2020.02.014

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents, Immunological / adverse effects*
Biopsy
Colon / diagnostic imaging
Colon / drug effects
Colon / immunology
Colon / pathology
Colonoscopy
Cyclosporine / therapeutic use*
Drug Resistance
Enterocolitis / chemically induced
Enterocolitis / diagnosis
Enterocolitis / drug therapy*
Enterocolitis / immunology
Female
Gastrointestinal Agents / pharmacology*
Gastrointestinal Agents / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use*
Infliximab / pharmacology
Infliximab / therapeutic use
Melanoma / drug therapy
Melanoma / immunology
Methylprednisolone / pharmacology
Methylprednisolone / therapeutic use
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Skin Neoplasms / drug therapy
Skin Neoplasms / immunology
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Gastrointestinal Agents
Immunosuppressive Agents
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Cyclosporine
Infliximab
Methylprednisolone